{"disease":{"id":"cns-metastases","name":"cns metastases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03275402","title":"131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Y-mAbs Therapeutics","has_results":true},{"nct_id":"NCT06552559","title":"Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06352502","title":"An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT06322342","title":"Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Reveal Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02650752","title":"Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}